Main Menu

Our Work

Sandoz Inc. and RareGen LLC v. United Therapeutics Corporation and Smiths Medical ASD, Inc.

In Sandoz Inc. v. United Therapeutics Corporation, Eric Gaier was retained on behalf of United Therapeutics Corporation (UTC) and Smiths Medical to testify regarding issues of market definition, market power, competitive effects, and irreparable harm. Plaintiffs Sandoz and RareGen alleged that defendants UTC and Smiths Medical blocked Sandoz from launching a generic formulation of UTC’s Pulmonary Arterial Hypertension drug, Remodulin®. Plaintiffs initially sought a preliminary injunction to access certain ambulatory infusion pumps manufactured by Smiths Medical and used to administer Remodulin® via subcutaneous injection. The District Court denied the plaintiffs’ motion for a preliminary injunction and subsequently granted the defendant’s motion for summary judgment on the antitrust allegations.

Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.